Dear All, I’ve previously written about the AMR Action Fund (9 Jul 2020 newsletter), a $1b fund created by 20+ global pharma with the intertwined goals of (i) bringing 2-4 new antibacterial antibiotics through Phase 2-3 and approval by 2030 and (ii) creating market conditions that enable sustainable investment in antibiotics. While we know that the
COVID-related heads-up: FDA has announced that VRBPAC (Vaccines and Related Biological Products Advisory Committee) will meet on 10 Dec 2020 to discuss the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19. Go here for details. Dear All, There’s a serious job opportunity in Singapore: The National University of Singapore seeks a full-time Director for
Dear All, The G20’s Global AMR R&D Hub (https://globalamrhub.org/, see below my signature for a brief history of the Hub) has a job opening from 1 Feb 2021 for a Scientific Program Officer. Here’s a brief description of the role: Contributes expert knowledge on AMR R&D to the further development of the Dynamic Dashboard and to
Dear All, First up today is a very interesting new workshop from FDA on 1-2 Sep entitled “Advancing the Development of Pediatric Therapeutics (ADEPT 7) Complex Innovative Trial Design.” In brief: “The Complex Innovative Trial Design Pilot Meeting Program (CID Program) facilitates and advances the use of complex and innovative trial designs that have the potential
Dear All, See below my signature: A 6-month consultancy with WHO to support the the SECURE initiative, a program to assist countries in accessing and sustainably managing new and existing antibiotics needed to cope with antimicrobial resistance (AMR). There’s not much online (yet) about SECURE: the best description I can find is in the Terms of Reference
Dear All, The Wellcome Trust Drug-Resistant Infections team wants to understand what researchers in academia and SMEs need to enable them to be better able to make progress with their early antibiotic discovery projects. Although some programs are now in place (e.g., the accelerator support provided by CARB-X), what are the remaining barriers? To help
Dear All, Quick note today as I am both exhausted and exhilarated by having listened to the all-day FDA Advisory committee on the Pfizer/BioNTech COVID vaccine: There is more to learn (the timelines are unlike anything you’ve ever seen before and include a Phase 1-2-3 trial design!!), but the efficacy is impressive and the risk/benefit
Dear All, As you know, WHO has been driving a series of clinical and preclinical pipeline reviews (go here for my current master list of pipeline reviews, including links to the 2017 and 2019 WHO reviews). In support of the next iteration of this review process, WHO have now posted (go here) a Geneva-based consultancy
Dear All, Two fascinating job opportunities have appeared. Even if you’re not looking for a job, the job descriptions tell you a lot about things going on below the surface: A role at the Associate or Full Professor level in Singapore The National University of Singapore is looking to appoint a Director for an innovative
Dear All, WHO today published a Request for Proposals (RFP) for a consultant to develop an online e-learning course on antimicrobial stewardship! There is a mention of the request on the WHO AMR homepage (link) which in turn takes you to the extended details in this Terms of Reference document (link). In brief, the project